US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery: market research reports

RSS Feeds

Drug Discovery market research reports and industry analysis

6  7  8  9    11    13  14  15  
Proteins in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 667 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 190 drugs. Proteins In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,746
Insomnia Global Clinical Trials Review, H2, 2014
7/14/2014 | published by: GlobalData
... relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
USD 2,500
Follicular Lymphoma - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various ...  |  read more...
USD 2,000
Arthritis - Pipeline Review, H2 2014
7/31/2014 | published by: Global Markets Direct
... Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of ...  |  read more...
USD 3,495
Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of ...  |  read more...
USD 3,495
Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of ...  |  read more...
USD 3,495
Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of ...  |  read more...
USD 3,495
Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of ...  |  read more...
USD 3,495
Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of ...  |  read more...
USD 3,495
Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of ...  |  read more...
USD 3,495
Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of ...  |  read more...
USD 3,495
PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023
7/31/2014 | published by: GlobalData
... sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn ...  |  read more...
USD 6,995
Clinical trials Market in India 2014
7/22/2014 | published by: Netscribes (India) Pvt. Ltd.
... as global pharmaceutical companies. Clinical trials are conducted on humans to examine the efficacy and safety of new drugs, treatments, therapies and new medical devices before launching them in the market. It is a necessary ...  |  read more...
USD 950
Mild Cognitive Impairment Global Clinical Trials Review, H1, 2014
6/20/2014 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Mild Cognitive Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
USD 2,500
NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. There are today 87 companies plus partners developing 75 NOD-like receptor signaling pathway targeting drugs in 239 developmental ...  |  read more...
USD 4,496
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... are today 229 companies plus partners developing 291 nucleic acid therapy drugs in 636 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last ...  |  read more...
USD 6,746
Orphan Drugs in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to ...  |  read more...
USD 6,746
p53 Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and ...  |  read more...
USD 4,496
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, ...  |  read more...
USD 6,746
RANKL Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C ...  |  read more...
USD 6,746
RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). There are today 58 companies plus partners developing 43 RIG-I-like receptor signaling pathway targeting drugs in ...  |  read more...
USD 2,246
RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... molecules or protein-based therapies. There are today 58 companies plus partners developing 107 RNA (miRNA, RNAi & siRNA) drugs in 144 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the ...  |  read more...
USD 4,496
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... cell receptor signaling. There are today 246 companies plus partners developing 359 T cell receptor pathway targeting drugs in 1278 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number ...  |  read more...
USD 6,746
6  7  8  9    11    13  14  15